Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR®
in Japanese Adults with Generalized Anxiety Disorder (GAD)
NewsletterReceive the most important news of the day by email
Treatment with once-daily EFFEXOR® met primary and all secondary efficacy
endpoints in outpatient adults with GAD.
7 hours ago
from: Longview News-Journal